Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Public ClinicalTrials.gov record NCT01927419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma
Study identification
- NCT ID
- NCT01927419
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2013 (Actual)
- Primary completion
- Jul 24, 2014 (Actual)
- Completion
- Feb 26, 2021 (Actual)
- Last update posted
- Mar 18, 2022
2013 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Oncology Associates | San Francisco | California | 94115 | — |
| Orlando Health Inc | Orlando | Florida | 32806 | — |
| University Of Louisville Medical Center, Inc., Dba | Louisville | Kentucky | 40202 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers Of Nevada | Las Vegas | Nevada | 89148 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| University Of New Mexico Cancer Center | Albuquerque | New Mexico | 87131 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering Nassau | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| St. Luke's Hospital | Easton | Pennsylvania | 18045 | — |
| GHS Cancer Institute | Greenville | South Carolina | 29615 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01927419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2022 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01927419 live on ClinicalTrials.gov.